New website is here!
Create an account to use the new features. Feel free to leave us feedback, constructive criticism welcome!

Avecho Biotechnology Ltd (ave) Logo

Avecho Biotechnology Ltd (AVE)

___:___ · AUD
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

AVE Chart

AVE's Principal Activity is the development, production, sale and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skin care and animal health and nutrition industries.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) +433.20%
vs ASX 200 (1yr) +428.06%

Size

Market Capitalisation
ASX Rank 1494 of 2,466
Sector Rank 129 of 177

Key Information

Shares Issued
Sector Healthcare
Similar Companies PAA / TD1 / RNO
EPS -$0.002
DPS $0.00
NTA per share $0.00

Broker Consensus

AVE is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Company Overview

Avecho Biotechnology Limited (AVE , formerly Phosphagenics Limited) develops and commercialises Human and Animal Health products using its proprietary drug delivery system called TPM (Targeted Penetration Matrix).

Incorporation Details

Incorporated in VIC on 19/06/1992 as Greenchip Development Capital Ltd. Name changed to Vital Capital Limited on 27/04/1999. Name changed to Phosphagenics Limited on 10/2/2004. Changed GICS from 4020 Diversified Financials to 3520 Pharmaceuticals & Biotechnology on 4/3/2005.

Corporate Details

Head Office Clayton VIC 3168
Website www.avecho.com.au
Registry Computershare
Auditor Grant Thornton Audit Pty Ltd
Date Listed 11 Aug 1993

Upcoming Calendar

Date Event
01/03/2021 Report (Prelim)
01/03/2021 Report (Annual)
27/08/2021 Report (Interim)

Dividend History

Ex-Date Amount Franking Gross Type Payable
22/09/2010 $0.03 0% $0.03 Final 21/10/2010
26/02/2010 $0.02 0% $0.02 Interim 24/03/2010
30/09/2009 $0.02 0% $0.02 Final 21/10/2009
26/02/2009 $0.02 0% $0.02 Interim 31/03/2009

See Upcoming Dividends for all ASX companies.

Key Data
DPS(TTM) $0.00
Gross DPS(TTM) $0.00
Dividend yield 0 %
Gross yield 0.00%
Payout Ratio 0%
DRP No
DRP Features -

Directors & Management

Directors & Management

Name Title Since Bio
Mr Matthew Patrick McNamara Non-Executive Director Jan 2020 Director Bio icon

Mr Matthew Patrick McNamara

Non-Executive Director

Mrt McNamara has over 30 years' experience in the healthcare and medical sciences sector. In 2003, he founded BioBridge Australia, a biotechnology commercialisation advisory company and advised a number of public biotechnology / investment companies. He is presently a director of Adherium Ltd (ASX:ADR), SciCapital Pty Ltd and Grey Innovation Group Pty Ltd. He has held previous directorship in, Avita Medical Ltd, Bioxyne Ltd, and Rex Bionics Pty Ltd. He has also served as CIO of BioScience Manager Pty Ltd, was CEO of SciCapital Pty Ltd, a Life Sciences Venture Capital fund, SVP Business Development for eBioinformatics Inc, General Manager of Vistakon Pty Ltd (a Johnson & Johnson Medical franchise), and held numerous management positions in Australia with Merck & Co.

Dr Gregory (Greg) Collier Non-Executive Chairman, Non-Executive Director Apr 2019 Director Bio icon

Dr Gregory (Greg) Collier

Non-Executive Chairman, Non-Executive Director

Dr Collier has more than 20 years' experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialisation. He has led the planning and execution of multiple commercial transactions including in and out licensing deals and major M&A activities, and he has taken a drug from discovery through to regulatory approval. Dr Collier was the inaugural Alfred Deakin Professor at Deakin University, and also held positions at Melbourne University, Monash University and the University of Toronto.

Mr David Segal Non-Executive Director May 2016 Director Bio icon

Mr David Segal

Non-Executive Director

Mr Segal was the Investor Relations Manager at Phosphagenics from 2011 to 2015. Prior to this he worked for over 30 years in stockbroking, including setting up, raising capital for and running Trent Securities which was absorbed into Shaw Stockbroking in 1992. Mr Segal has been a shareholder of Phosphagenics since 1999.

Professor Andrew Lancelot Vizard Non-Executive Chairman, Non-Executive Director Nov 2015 Director Bio icon

Professor Andrew Lancelot Vizard

Non-Executive Chairman, Non-Executive Director

Professor Vizard is a Principal Fellow at the Faculty of Veterinary and Agricultural Sciences, University of Melbourne and previously Associate Professor of Veterinary Epidemiology and Director of The Mackinnon Project. He is an experienced company director and has previously held directorships in Animal Health Australia and Primesafe. In the previous four years, Professor Vizard was a non-executive director of the Ridley Corporation Limited. He is Member of Risk Management Committee.

Dr Ross Murdoch Non-Executive Director Apr 2015 Director Bio icon

Dr Ross Murdoch

Non-Executive Director

Dr Murdoch joined Phosphagenics as CEO in January 2015 and was appointed as director in April 2015. He has more than 25 years' experience as a leader within the global healthcare, pharmaceutical and biotechnology industries. He has held senior management and executive positions in Australia, the USA and Europe, with responsibility for the strategy, development and commercialisation of products, product portfolios and the building and rebuilding of new and existing businesses. Highlights of his career include Senior Vice President at Shire Pharmaceuticals where he founded and grew both the Emerging Products Business and Haematology Business, and President and COO of Prana Biotechnology Limited based in Australia.

Mr Lawrence Gozlan Non-Executive Director Aug 2011 Director Bio icon

Mr Lawrence Gozlan

Non-Executive Director

Mr Gozlan is the Chief Investment Officer and Founder of Scientia Capital, a investment fund which has focus in life sciences. Prior to this, Mr Gozlan was in charge for the biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC ("the Queensland Investment Corporation"). He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking Pty Ltd, and gained senior corporate finance experience advising life sciences companies at Deloitte. Mr Gozlan is currently direcor of number of private biotechnology companies in the USA.

Mr Donald Ian Clarke Non-Executive Director, Non-Executive Deputy Chairman Aug 2009 Director Bio icon

Mr Donald Ian Clarke

Non-Executive Director, Non-Executive Deputy Chairman

Mr Clarke is s a lawyer and company director. In addition to being a consultant to the law firm, Minter Ellison (having retired on 30 June 2015 after 27 years as a corporate partner of the firm), Don is a director of the listed companies, Zoono Group Limited and Contango Income Generator Limited, and two other unlisted public companies. He has extensive commercial law and business experience from over 30 years advising ASX listed and private companies.

Mr Jonathan Lancelot Addison Non-Executive Director Apr 2005 Director Bio icon

Mr Jonathan Lancelot Addison

Non-Executive Director

Mr Addison has over 34 years of experience in the investment management industry. He is Investment consultant and former CEO of the Meat Industry Employees Superannuation Fund. Previous experience includes Director and Asset consultant with the Corporate Finance Section of Pricewaterhouse Coopers and Manager at Sedgwick Noble Lowndes. He is Chairman of Gardior Pty Ltd, Chairman and Member of Investment, Committee of Centaur Property Funds Management Ltd, Director CHIF Pty Ltd and Director Ballarat Water Pty Ltd.

John Mills N/A
Peter Lankau N/A
Michael Ashton N/A
Harry Rosen N/A
Stuart James N/A
Sandra Webb N/A
Nathan Drona N/A
Esra Ogru N/A
Geert Cauwenbergh N/A

Director Interests

The current holdings of AVE directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Ross Murdoch 26/02/2020 1,666,667 N/A 0 N/A
Matthew McNamara 13/01/2020 0 N/A N/A N/A
David Segal 31/12/2019 11,795,920 6,695,361 1,500,000 N/A
Gregory (Greg) Collier 31/12/2019 N/A 2,000,000 2,250,000 N/A

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Feb 21, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Mr Mark Gregory Kerr (Lindmark Inv Staff S/F A/C) 93,071,745 5.90%
HSBC Custody Nominees (Australia) Limited 86,209,916 5.47%
Mr Mark Gregory Kerr & Mrs Linda Marie Kerr (Lindmark Inv Staff S/F A/C) 67,153,797 4.26%
BNP Paribas Noms Pty Ltd (DRP) 41,991,591 2.66%
Paradyce Pty Ltd (The Paradyce A/C) 38,600,000 2.45%
Rosscope Pty Ltd (Ross Copeland Family A/C) 30,558,184 1.94%
Mr Ross Copeland & Mrs Gina Copeland 23,018,212 1.46%
ACK Pty Ltd (Markoff Super No 2 A/C) 20,494,147 1.30%
Kazakco Pty Ltd (Kent Family A/C) 20,000,000 1.27%
Citicorp Nominees Pty Limited 19,944,950 1.26%
Churchcourt Pty Limited 19,162,500 1.21%
Mr Ross Graham Copeland & Mrs Gina Copeland (Publicity Press S/F A/C) 16,868,545 1.07%
Mr Brandon Armon Batagol 16,005,597 1.01%
Dr Maurice Arthur Trewhella & Mrs Elizabeth Trewhella (Simpetejen Super Fund A/C) 16,000,000 1.01%
Servbond Pty Limited (Servbond Pty Ltd S/F A/C) 16,000,000 1.01%
Citycastle Pty Ltd 15,600,000 0.99%
BHL Pension Pty Ltd (BHL Pension Fund A/C) 15,000,000 0.95%
Mr Gary Dean Shaw 15,000,000 0.95%
Mrs Susan Margaret Chudleigh & Mr John West Chudleigh 14,000,000 0.89%
J P Morgan Nominees Australia Pty Limited 13,166,434 0.83%

Shareholder Distribution

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 459 903 671 2,016 1,188 5,237

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held under multiple names so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Name Last Notice Total Shares Shares Held (%)
Mark Gregory KERR 21/02/2020 199,503,526 12.65

Shareholders Buying

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $0.007 30 June
2019 $0.003 28 June
Page Icon
AVE Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.